Study of Renal Autologous Cell Therapy (REACT) in Subjects With Type 1 or 2 Diabetes and Chronic Kidney Disease (REGEN-007)

Prokidney53 enrolled

Overview

The purpose of this study is to assess the safety, efficacy, and durability of up to two REACT injections delivered percutaneously into biopsied and non-biopsied contralateral kidneys on renal function progression in two different cohorts of subjects with T1DM or T2DM and CKD.

The objective of this study is to assess the safety, efficacy, and durability of up to two REACT injections delivered percutaneously into biopsied and non-biopsied contralateral kidneys on renal function progression in two different cohorts of subjects with T1DM or T2DM and CKD: * Cohort 1: Two scheduled REACT injections given 3 months (+60 days) with at least 18- month follow-up * Cohort 2: One scheduled REACT injection with a possible second REACT injection, no less than 3 months after the first one, within 30 days (+30 days) of meeting a renal function redose trigger (triggered up to 15 months following the first REACT injection). Both cohorts will be followed for 18 months after the final REACT injection. If a Cohort 2 subject does not meet a trigger, the subject will be followed for at least 18 months after the first injection.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Chronic Kidney Diseases Type 1 Diabetes Mellitus Type 2 Diabetes Mellitus

Interventions

Renal Autologous Cell Therapy (REACT)BIOLOGICAL

Autologous selected renal cells (SRC)

Eligibility

Sex: ALLMin age: 30 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Male or female aged 30 to 80 years, inclusive, on the date informed consent is signed. 2. Clinical diagnosis of T1DM or T2DM, controlled per institutional standard of care. 3. The subject has a clinical diagnosis of diabetic nephropathy as the underlying cause of renal disease (diagnosis does not have to be confirmed via renal biopsy). 4. The subject has a serum glycosylated hemoglobin (HbA1c) level less than 10% at the Screening Visit. 5. The subject has a documented clinical diagnosis of an eGFR between 20 and 50 mL/min/1.73m² inclusive not requiring renal dialysis. Exclusion Criteria: 1. The subject has a history of renal transplantation. 2. The subject has a mean systolic blood pressure greater than or equal to 140 mmHg and/or mean diastolic blood pressure greater than or equal to 90 mmHg at screening. Subjects with blood pressure outside of this range prior to biopsy/injection may continue if approved by the Medical Monitor. 3. The subject has hemoglobin levels less than 10 g/dL and is not responsive to the standard medical intervention for CKD-related anemia prior to randomization.

Locations (5)

Kidney Associates of Colorado, P.C. - Frenova

Denver, Colorado, United States

Nephrology Associates

Newark, Delaware, United States

Boise Kidney and Hypertension Institute - Frenova

Nampa, Idaho, United States

Paragon Health, PC d/b/a Nephrology Center, PC - Frenova

Kalamazoo, Michigan, United States

Outcomes

Primary Outcomes

Improvement in renal function progression rate as indicated by the change from pre-injection baseline value in total (acute + chronic) slope of estimated glomerular filtration rate (eGFR) using the CKD-EPI 2009 equation

Time frame: Screening thru month 28

Procedural and investigational product-related treatment-emergent adverse events (TEAEs) obtained through 18 months after the last REACT injection.

Time frame: Screening thru 18 months after the last injection of study drug

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.